Adlai Nortye Ltd (ANL): Rasio rega marang pendapatan

Tandha merek Adlai Nortye Ltd. (ANL)

Adlai Nortye Ltd. (ANL) develops advanced drug combinations to combat resistant tumors, leveraging a flexible network of regional supply hubs and a global network of clinics across Europe, China, and the US. The market capitalization-to-revenue ratio confirms these fundamental successes, with the current parameter equal to 34.50, helping investors assess the business's market value relative to its turnover.

Multiplikator P/S: Adlai Nortye Limited (ANL) kanggo 13.04.2026 - 16.11.2026

Rincian metrik lan analitis perusahaan Adlai Nortye Limited (ANL)

- rega saham lan target rega konsensus:
Analisis fundamental perusahaan:ANL - Adlai Nortye Ltd.
Produk dadi Adlai Nortye Ltd

Adlai Nortye Ltd. (ANL) operates a high-risk oncology development business without commercial sales. In the absence of operating profit, the market capitalization-to-revenue ratio reflects a speculative valuation of future clinical trial successes. This multiple compares the total equity value with the volume of incoming partner contributions, measuring the premium for innovation potential. High indicator values signal inflated market expectations relative to the issuer's current financial resources.

Pesaing Adlai Nortye Ltd.

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd